Abstract 669P
Background
Selpercatinib, a first-in-class highly selective and potent rearranged during transfection (RET)-inhibitor, demonstrated efficacy in treatment of RET-driven cancers in the phase 1/2 LIBRETTO-001 trial. We report patient-reported outcomes for non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), non-MTC thyroid cancer (TC) (15 Jun 2021, data cut-off date) and tumor agnostic (TA) cohorts (24 Sep 2021, data cut-off date).
Methods
Patients completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) at baseline (BL), approximately every 8 weeks until cycle 13, and then every 12 weeks until end of treatment (EoT). Subscales were scored 0–100; higher scores indicate better functioning or more severe symptoms based on the subscale. Proportion of patients with improved, stable, or worsened status post-BL was assessed. For symptom subscales improved is 10-point decrease from BL, worsened is 10-point increase from BL, and stable is being within 10 points from BL. For other subscales improved is 10-point increase from BL, worsened is 10-point decrease from BL, and stable is being within 10 points from BL.
Results
For patients with NSCLC, MTC, TC, and TA, respectively, 200 (63%), 208 (71%), 32 (70%), and 28 (68%) patients completed BL assessment; compliance rate was 85%, 87%, 72%, and 86%. BL functional domain subscale scores were >65 points across cohorts. Mean (SD) BL global health status (GHS) scores were: NSCLC – 62 (24), MTC – 65 (24), TC – 73 (20), and TA – 59 (26). The highest BL symptom scores (mean [SD]) were: NSCLC – fatigue (37 [26]) and dyspnea (30 [29]), MTC – diarrhea (42 [38]) and fatigue (36 [27]), TC – insomnia (28 [27]) and fatigue (27 [24]), and TA – fatigue (40 [29]) and appetite loss (37 [36]). Change in post-BL status varied across cohorts (Table).
Table: 669P
Proportion of patients with post-BL response (Cycle 3 to EoT), mean (SD) | ||
NSCLC | ||
GHS | Improved | 42 (9) |
Stable | 42 (10) | |
Worsened | 17 (8) | |
Fatigue | Improved | 44 (7) |
Stable | 27 (5) | |
Worsened | 29 (9) | |
Dyspnea | Improved | 34 (6) |
Stable | 57 (5) | |
Worsened | 9 (4) | |
MTC | ||
GHS | Improved | 37 (7) |
Stable | 45 (4) | |
Worsened | 19 (7) | |
Fatigue | Improved | 46 (6) |
Stable | 28 (5) | |
Worsened | 26 (8) | |
Diarrhea | Improved | 53 (5) |
Stable | 35 (3) | |
Worsened | 12 (4) | |
TC | ||
GHS | Improved | 21 (9) |
Stable | 54 (8) | |
Worsened | 25 (6) | |
Fatigue | Improved | 39 (10) |
Stable | 32 (14) | |
Worsened | 30 (11) | |
Insomnia | Improved | 24 (14) |
Stable | 56 (7) | |
Worsened | 21 (13) | |
TA | ||
GHS | Improved | 39 (10) |
Stable | 44 (8) | |
Worsened | 17 (4) | |
Fatigue | Improved | 49 (12) |
Stable | 19 (9) | |
Worsened | 33 (11) | |
Appetite loss | Improved | 44 (9) |
Stable | 51 (13) | |
Worsened | 5 (6) |
Conclusions
The majority of patients with RET-driven cancers remained stable or improved on most QLQ-C30 domains during treatment with selpercatinib.
Clinical trial identification
NCT03157128.
Editorial acknowledgement
Leo J. Philip Tharappel, an employee of Eli Lilly Services India Private Limited provided medical writing and editorial assistance.
Legal entity responsible for the study
Eli Lilly and Company.
Funding
Eli Lilly and Company.
Disclosure
H. Kang: Financial Interests, Institutional, Research Funding, clinical trial contract: Eli Lilly and Company, Exelixis; Financial Interests, Personal, Speaker, Consultant, Advisor, honorarium: AXIS Med. L.E. Raez: Financial Interests, Personal and Institutional, Research Funding: Loxo, Eli Lilly and Company, Genentech, Pfizer, Novartis, Syndax, Guardant, Nanth Health, Natera, BMS, Merck, Velos. M. Khanal, Y. Han, S. Szymczak, S. Barker, A.M. Gilligan: Financial Interests, Personal, Full or part-time Employment: Eli Lilly and Company; Financial Interests, Personal, Stocks/Shares: Eli Lilly and Company. K. Wang: Financial Interests, Personal, Full or part-time Employment: TigerMed Grp. All other authors have declared no conflicts of interest.
Resources from the same session
116P - Circulating tumour DNA- based minimal residual disease detection for biliary tract cancer
Presenter: Zhishuai Li
Session: Poster session 17
117P - Genomic landscape of biliary tract cancers from India show distinct geographic variation
Presenter: Nitesh Rohatgi
Session: Poster session 17
118P - Artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker for anti-PD-1 in advanced biliary tract cancer (BTC)
Presenter: Yeonghak Bang
Session: Poster session 17
119P - Management of biliary tract cancers in older patients: A French multicenter cohort study
Presenter: Marine Valery
Session: Poster session 17
120P - Management of biliary tract cancers in early onset patients: A French multicenter real-life study from the ACABI-PRONOBIL cohort
Presenter: Antoine Lebeaud
Session: Poster session 17
121P - PemiBil: Efficacy and safety of pemigatinib in advanced cholangiocarcinoma with FGFR2 fusions/rearrangements in real-world, results of multicentric French cohort from ACABI consortium
Presenter: Blandine Delaunay
Session: Poster session 17
122P - Largest examination of cholangiocarcinoma (CCA) patients (pts) treated with novel targeted therapies after extended molecular profiling on liquid biopsies
Presenter: Umair Mahmood
Session: Poster session 17
123P - Artificial intelligence (AI)-powered analysis of human epidermal growth factor receptor-2 (HER2) and tumor-infiltrating lymphocytes (TILs) in advanced biliary tract cancer (BTC)
Presenter: Gwangil Kim
Session: Poster session 17
124P - Clinicopathological nomogram for predicting fibroblast growth factor receptor 2 (FGFR2) gene fusion/rearrangement (F/R) in intrahepatic cholangiocarcinoma (iCCA)
Presenter: Maria Bensi
Session: Poster session 17
125P - Real-world treatment patterns in patients with biliary tract cancer (BTC): Retrospective chart review survey in Europe (GARNET-2)
Presenter: John Bridgewater
Session: Poster session 17